Extended Data Fig. 9: Relationships between frequencies of CD39⁺ CD8⁺ TILs and clinical parameters of colorectal cancer patients.

a, Mass cytometry dot plots representing expression of CD39 by CD8⁺ TILs in lung and colorectal tumours. Representative data from two patients. Data are from at least ten independent mass cytometry experiments. b, CD39⁺ cells as a percentage of CD8⁺ TILs stratified by microsatellite-stable (MSS) (n = 3 patients) or microsatellite-instable (MSI) (n = 33 patients) status. Data are means from at least ten independent mass cytometry experiments. c, Mutation rate (in mutational events per megabase, plotted on a log scale) versus CD39⁺ CD8⁺ TIL frequencies in colorectal tumours (n = 26 patients). Data from at least ten independent mass cytometry experiments. d, Box plots representing CD39⁺ frequencies among CD8⁺ TILs stratified by the consensus molecular subtypes of each tumour. CMS1 (n = 6 patients), CMS2 (n = 34 patients), CMS3 (n = 8 patients), CMS4 (n = 3 patients). Box plots show the median, box edges represent the first and third quartiles, and the whiskers extend from minimum to maximum. Data are from at least ten independent mass cytometry experiments. e, Dot plots representing CD39⁺ frequencies among CD8⁺ TILs stratified by tumour stages. Stage I (n = 6 patients), stage II (n = 10 patients), stage III (n = 10 patients), stage IV (n = 8 patients). Data are mean ± s.d. from at least ten independent mass cytometry experiments. f, Number of driver mutations against CD39⁺ CD8⁺ TILs frequencies in colorectal tumours. Two-tailed t-test; Pearson’s correlation. n = 27 patients. Data are from at least ten independent mass cytometry experiments.